Treatment outcome of Ph⁺ ALL according to prednisone response and treatment. (M)M(U)RD, allogeneic HLA-(mis)matched (un)-related donor BMT; PGR, prednisone good response; PPR, prednisone poor response; PRNE, prednisone response not evaluable; DOD/DOT, died of disease/toxicity. Follow-up details (refer to Table1): (a) patient no. 21: BMT, in CR2; no. 24: BMT after second relapse, in CR3; no. 31 and 42 without BMT in CR2 at 30+ and 41+ months, respectively; (b) patients no. 23, 25, 33, 36, 44, 55, and 57: 1 MRD BMT: second relapse, 1 MURD BMT after second relapse; maximum survival time after relapse 48 months; (c) patient no. 27: CR2 59+ months, no BMT after relapse; (d) patients no. 26 (MMRD), 29 (MMURD), 43, and 46 (MURD): lethal complications related to acute GVHD; (e) patients no. 5, 6, 9, 11, 12, 19, and 20: no BMT after relapse, maximum survival time after relapse 6 months; (f) patients no. 3, 4, and 10: maximum survival time after relapse 3 months; (g) patients no. 7, 8, and 14: died of acute BMT-related complications at 1.5, 2, and 5 months after BMT, respectively; (h) patients no. 59 and 61: both transplanted after relapse, maximum survival after relapse of 8 months; (i) patient no. 60: died of acute GVHD, not being in CR.